試題詳解

66. HCC systemic therapy，依據 phase 3 clinical trials 的結果，其 overall survival相對於 sorafenib 的 HR(hazard ratio)，由小至大排列順序，何者正確？
(1) IMbrave 150, Atezolizumab + Bevacizumab
(2) HIMALAYA, STRIDE: Tremelimumab + Durvalumab
(3) COSMIC-312, Cabozantinib + Atezolizumab
(4) CARES-310, Camrelizumab + Rivoceranib
(A) (1)—(2)—(4)—(3)
(B) (1)—(4)—(2)—(3)
(C) (2)—(1)—(3)—(4)
(D) (4)—(2)—(1)—(3)

(E) (4)—(1)—(2)—(3)